Overview of HBV major genotypes and its distribution pattern
Hepatitis B Virus (HBV) infection is a global health problem: an estimated two billion people (one-third of the global population) have been infected with HBV at some point in their life; of these, more than 350 million suffer from chronic HBV infection, resulting in over 600,000 deaths each year, mainly from cirrhosis or liver cancer . More than 10% of the global chronic HBV population resides in India ; infection may lead to liver damage that results in acute or chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) (Figure 1). HBV infection was first identified in 1965 when Blumberg and co-workers  found the hepatitis B surface antigen (HBsAg), originally termed as
1.1. HBV evolution
The history and origin of HBV is partially understood. The evolution of HBV can be traced from lowest vertebrates such as the birds infecting virus i.e. avian hepadnavirus which shares a sequence homology of 40%, non-primate such as rodents infecting wood chuck HBV viruses shares 80% homology [4, 5]. However, highest incidence of greater than 94% of homology is found to occur in primates infecting viruses suggesting an evolutionary sequence for the human HBV .
The long time evolution of HBV therefore leads to the occurrence of various genotypes, subgenotypes, mutants, recombinants and even quasispecies . Major forces such as genetic drift, bottle neck effects, founder effects and recombination played a vital role in evolution, adaptation of HBV and become a successful pathogen in the host. The genetic variability, in conjunction with the migration of human race, has led to the divergence of HBV into genetically different groups, called genotypes, with a distinct geographic distribution. Some researchers suggest that HBV co-evolved with modern humans, as they migrated from Africa, around 100,000 years ago [8,9]. Based on the prevalence, geographic distribution and characteristic of recombinant genotypes, it can be suggested that genotypes A and D co-exist over a relatively long period, while genotypes B and C are believed to have recent epidemiological contact in Asia . The genetic diversity of HBV and its geographical distribution may help us to reconstruct the evolutionary trend of HBV. This may help to generate additional genetic data on the evolution and migration pattern of man .
1.2. Hepatitis B virus: Molecular virology
HBV is a hepatotropic, non-cytopathic virus and a prototype member of the family
1.3. Viral entry and replication
HBV has a high degree of species and tissue specificity that results in very high levels of viral replication without actually killing the infected cell directly. The mechanism through which HBV enters hepatocyte or other susceptible cells remains elusive mostly owing to lack of a proper cell culture system. As a pararetrovirus, HBV uses reverse transcription to copy its DNA genome and lack of proof-reading capability permits the emergence of mutant viral genomes and quasispecies.
Upon infecting a hepatocyte, the HBV genome is delivered in to the nuclear compartment where cellular repair enzymes are involved in repairing the viral genome into covalently closed circular DNA (cccDNA). This viral DNA acts as a transcriptional template [11, 12] for the generation of the pregenomic mRNA (pg mRNA), pre-core mRNA and all other subviral mRNAs [13, 14]. Subsequently, cccDNA is chromatinized into viral minichromosome that ultimately serves as an intrahepatic reservoir of HBV and stays throughout the life of the chronically infected host [15, 16]. The pregenomic RNA is encapsulated by the virion core particle and reversely transcribed by the viral polymerase, forming a single-strand DNA (negative strand). Subsequently, the pregenome is degraded and the negative strand DNA then acts as a template for synthesis of a positive strand DNA with variable length. Finally, the HBV genome is either encapsulated to produce virions to be secreted out, or recycled back to the nucleus to maintain a pool of cccDNA, resulting in the formation of a steady-state population of 5–50 copies of cccDNA molecules per infected hepatocyte [14, 17] (Figure 3).
2. HBV genomic organization and proteins
The HBV genomes comprise a partially double-stranded 3.2kb DNA molecule, organized into 4 overlapping open-reading frames (ORFs). Four sets of mRNAs are then transcribed from the viral minichromosomes using host cell machinery, RNA polymerase II. These molecules are then transported by cellular proteins to the cytoplasm where they are translated to produce the viral proteins: hepatitis B core antigen (HBcAg or nucleocapsid protein from the 3.5 kb RNA); the soluble and secreted hepatitis B e antigen (HBeAg, from the 3.5 kb RNA ); the Pol protein (from the 3.5 kb RNA, which is longer than the viral entire genome); the viral envelope proteins HBsAg (from the 2.4 and 2.0 kb RNAs) and hepatitis B X protein (HBx from the 0.7 kb RNA). The dynamic nature of individual viral proteins and insufficient immune response elicited by the infected host immune cells lead to the persistence of HBV infection
2.1. Hepatitis B virus surface antigen (HBsAg)
Since Blumberg’s discovery of HBsAg in 1965, it has been used as the hallmark for the diagnosis of HBV infection . HBsAg is the prototype serological marker of HBV infection that characteristically appears after 1 to 10 weeks of an acute exposure to HBV but before the onset of visible symptoms or elevation of serum alanine aminotransferase (ALT) . HBsAg circulates in a wide array of particulate forms such as competent virions (42 nm, Dane particles), 20 nm diameter filaments of variable length, and 20–22 nm spherical defective particles, corresponding to empty viral envelopes. It exceeds virions by a variable factor of 102 – 105 and accumulates several hundred micrograms per ml of serum . The principal function of the HBs protein as a virological structure is to enclose the viral components, in addition to playing a major role in cell membrane attachment to initiate the infection process by binding to the hepatocyte plasma membrane . Persistence of HBsAg for more than 6 months indicates chronic infection and it is estimated that fewer than 5% of immunocompetent adult patients with acute hepatitis B progress to chronic infection . The immune response enhancing ability of HBsAg is not clear yet it is understood that large amounts of HBsAg may induce T cell anergy, leading to decreased antibody-mediated neutralization of HBV and generalized hyporesponsiveness towards pathogens.
2.2. Hepatitis B core antigen (HBcAg)
HBcAg is the major constituent of the nucleocapsid, which is essential for viral replication. It also forms a part of ichosahedral subviral particles that packs the viral reverse polymerase and the pregenome  derived from the ORF-C. It has either 183 or 185 amino acids depending on the genotype of the virus. HBcAg is a particulate and multivalent protein antigen which can function as both a T cell-independent and a T cell-dependent Ag  and is ~1000 fold more immunogenic than the HBeAg . The response of T cells to HBcAg has been reported to contribute to the resolution and seroconversion in chronic hepatitis B .
2.3. Hepatitis B envelope antigen (HbeAg)
HBeAg is an accessory protein of HBV, not essential for replication
HBeAg is a non-particulate secretory protein discovered by Magnius and Espmark in 1972 . It is derived after cleavage from a 212 amino acid precursor, precore protein that is encoded by the HBV precore gene (the pre-C sequence and C-gene). It is highly conserved evolutionarily between all
HBeAg is found at concentrations of greater than 10μg mL-1 in the plasma, which can be detected even by agar-gel immunodiffusion. Secreted HBeAg has an immunoregulatory function
2.4. Hepatitis B X antigen (HBxAg)
HBx antigen, a 17 kDa multifunctional, non-structural protein, comprised of 154 amino acids, which is conserved across all the mammalian infecting
Accumulating evidences indicate that the HBV X gene is indispensable to HBV replication, propagation and integration of viral DNA into the host’s genome. The expression of full-length HBx protein is dispensable for virus production
3. HBV viral load
HBV is reported to be present in the blood of HbeAg seropositive individuals at a concentration of approximately 108–109 viral particles mL-1 of blood . HBV DNA is present in high titers in blood and exudates of in acute as well as chronic cases. Generally, moderate viral titers are found in saliva, semen and vaginal secretions [45, 46]. The serum levels of HBV DNA largely depend on the viral genotype, and the quantity of HBeAg in serum, which determines the progression of liver cirrhosis to carcinoma.
3.1. HBV genotypes and subgenotypes
The global HBV genome diversity is influenced by both genotypic and phenotypic variability; genotypes often evolve in the absence of selective pressure but phenotypic variability often develops in the presence of selective pressure exerted by host immune system or even during certain therapeutic measures .
This genetic diversity of HBV has been associated with differences in clinical and virological characteristics, indicating that they may play a role in the virus–host relationship . Genotypes may result from neutral evolutionary drift of the virus genome, from recombination, or as a consequence of a long-term adaptation of HBV to genetic determinants of specific host populations. Structural and functional differences between genotypes can influence the severity, course and likelihood of complications, HBeAg seroconversion and response to treatment of HBV infection and possibly the vaccination against the virus .
Traditionally HBV was classified into 4 subtypes or serotypes (adr, adw, ayr, and ayw) based on antigenic determinants of HBsAg . In the advent of more molecular approaches, serotyping of viral strains was replaced by various genotyping methods. Galibert
3.2. HBV Genotyping
Currently, more than 10 different methods have been developed for HBV genotyping with variable sensitivity, specificity, turnaround time and cost. These methods include restriction fragment length polymorphisms (RFLP) , PCR with specific primers for single genotypes , multiplex-PCR for many HBV genotypes [62, 63] and on hybridization technologies  or real time quantification and genotyping  or Mass spectrometry . The gold standard method for HBV genotyping is a complete genome sequencing followed by phylogenetic analysis of the sequence divergence [9, 52]. Sequence and phylogenetic analysis can also be performed on individual genes, more often in envelope (S) gene. The reliability of using individual genes or limited gene sequence will depend both on the size of the sequence analyzed and the degree of sequence homology. The HBV genotype can be determined by other methods that are based on a limited number of conserved nucleotide or amino acid differences between the genotypes. Line probe assay (LiPA) may be a suitable alternative to sequencing but it is expensive when compared to other methods such as multiplex PCR, RFLP and serotyping. Based on the sensitivity, other methods such as microarrays, real time PCR, reverse dot blot, restriction fragment mass polymorphism (RFMP), invader assay are being used [67,68]. Identification of HBV genotypes will be useful to understand the source of infection, predict clinical outcome at individual level and monitoring the development of newer viral strains at population level.
3.3. Clinical implications of HBV genotyping
Mounting evidence shows that HBeAg seroconversion rates, HBcAg seroconversion, viremia levels, viral latency, immune escape, emergence of mutants, pathogenesis of liver disease, response and resistance to antiviral therapy are all depend on the HBV genotypes and subgenotypes. Individual or combinations of the above factors are responsible for the degree of clinical heterogeneity displayed by the infected persons [69, 70].
Earlier reports from India, where genotypes A, D are prevalent and patients infected with genotype D had relatively high degree of disease severity and develop HCC . Patients with genotypes C and D have a lower response rate to interferon therapy than patients infected with genotypes A or B [71,72]. An Alaskan population study which compares the clinical virological properties of five genotypes has shown that the mean age seroconversion from HBeAg to anti-HBe is significantly lower among genotypes A, B, D and F, than compared to genotype C . This may be due to the development of more mutations in the basal core promoter region of genotypes C and D compared to genotypes A and B. Genotype G appears defective, and usually occurs together with another genotype, which provides transcription factors necessary for replication. Viral load of the patients with genotype mixture is usually higher than that of those infected with unique genotype.
3.4. HBV mutant (Phenotypic variants)
Phenotypic variants emerge in response to selective pressure . Development of HBV mutants are often related to the persistence of cccDNA and viral factors such as the existence of quasispecies, high rate of HBV replication, error prone RT-based life cycle and adaptive mutants with compensatory mutations. Host factors include compliance with antiviral therapy, immune response, enhanced hepatic inflammatory response and host genetic background. HBV quasispecies arise due to the average daily production of >1011 virions with a error rate of 1.4-3.2 x 10-5 nucleotide substitutions per site per year, which results in production of all possible number of different single base changes in the HBV genome [74-76]. Active replication leads to an estimated misincorporation rate of around 104 owing to the lack of proof-reading (3’ – 5’ exonuclease activity) . The combination of a high error rate together with an increased replication rate produces as high as 109 mutation day-1 over the entire 3.2kb genome [74, 78] but, the extreme overlapping of the ORF of the HBV genome limits the possibility of all these mutations .
Moreover, mutations in the HBV genome seem to play a vital role in differential outcome of this infection (Table 2). Two important mutations in the HBV virus have been associated with differential outcome such as the basal core promoter (BCP) mutation and the pre-core (PC) mutation. BCP mutation is a double substitution, A1762T, G1764A, in the basal core region of HBV. It has clearly been associated with an increased risk of HCC and cirrhosis in multiple studies, both cross-sectional and prospective .
Antiviral medications for the management of chronic HBV infections currently available include alpha interferon (IFN-α) and three nucleoside analogs: lamivudine, adefovir and entecavir that inhibit viral nucleocapsid formation and block viral DNA synthesis by premature chain termination [81,82]. The major determinant involved in the selection of drug-resistant mutation is the fitness of the mutants and the replication space available for the spread of mutants. In chronic hepatitis B, the replication space is provided by hepatocyte turnover, which allows the loss of HBV wild-type infected cells and the generation of non-infected hepatocytes that are susceptible to new HBV mutant infections. Long-term therapy of adefovir or entecavir mediates significant reduction in cccDNA, but still fails to eliminate chronic HBV infections [83, 84].
Among all forms of viral hepatitis, HBV infection is considered as a major infectious disease due to the broad range of clinical spectrum and the progressive complications displayed by the infected individuals. Avians, rodents and human forms of the virus have been recognized for many years and infections were assumed to be highly host specific. The geographic pattern of HBV genotype distribution is not only influenced by the host and viral factors but also by socio-economical factors like migration and immigration of people, availability of vaccine and anti-viral therapeutics. The genetic diversity of HBV has been associated with clinical outcome, and response to antiviral therapy. Various forces like natural selection pressure, antiviral drug mediated pressure and error prone high replication rate are the important factors responsible for this genetic diversity. The final outcome from this infectious disease is solely determined by specific interaction between viral components and immunogenetics of the host. Understanding the influence and the role of viral genetic diversity is considered as a prerequisite to better the treatment options.
Hepatitis B: World Health Organization Fact Sheet;who.int/mediacentre/factsheets/fs204/en/ c2008updated august 2008] Available from: http://www
Sarin S. K et al 2001 Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations.J Gastroenterol. Hepatol. 16 6 666 73
Blumberg B. S et al 1965 A new antigen in leukemia sera.JAMA. 191 541 6
Mandart E et al 1984 Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.J Virol. 49 3 782 92
Galibert F et al 1982Nucleotide sequence of a cloned wood chuck hepatitis virus genome: comparison with hepatitis B virus sequence. J Virol. 41 1 51 65
MacDonald DM et al 2000Detection of Hepatitis B Virus Infection in Wild-Born Chimpanzees (Pan troglodytes verus): Phylogenetic relationship with human and other primate genotype. J. Virol. 74 9 4253 57
and Lau J. Y Wright T. L 1993 Molecular virology and pathogenesis of hepatitis B. 342 8883 1335 40
Norder H et al 2004 Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes 47 6 289 309
Norder H et al 1994 Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. 198 2 489 503
and Fares M. A Holmes E. C 2002 A revised evolutionary history of hepatitis B virus (HBV).J Mol Evol. 54 6 807 14
Liang T. J 2009Hepatitis B: the virus and disease.Hepatology. 49 5 13 21
and Ganem D Prince A. M 2004Hepatitis B virus infection- natural history and clinical consequences. N Engl J Med. 350 11 1118 29
and Seeger C Mason W. S 2000 Hepatitis B virus biologyMicrobiol Mol Biol Rev. 64 1 51 68
Tuttleman J. S et al 1986 Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. 47 3 451 60
Bock C. T et al 2001 Structural organization of the hepatitis B virus minichromosomeJ Mol Biol. 307 1 183 96
Zhu Y et al 2001 Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesisJ Virol. 75 1 311 22
Wu T. T et al 1990 In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. 175 1 255 61
Blumberg B. S et al 1986 Hepatitis and leukemia: their relation to Australia antigen.Bull N Y Acad Med. 44 12 1566 86
Krugman S et al 1979 Viral hepatitistype B. Studies on natural history and prevention re-examined. N Engl J Med. 300 3 101 6
Pontisso P et al 1989 Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. 173 2 522 30
Mcmahon B. J et al 1985 Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier stateJ Infect Dis. 151 4 599 603
Crowther R. A et al 1994 Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. 77 6 943 50
and McLachlan ( Milich D. R 1986 The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen 234 4782 1398 1401
Milich D. R et al 1988 Comparative immunogenicity of hepatitis B virus core and E antigens.J Immunol. 141 10 3617 24
Lau G. K et al 2002 Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. 122 3 614 24
Chen H. S et al 1992The precore region of an avian hepatitis B virus is not required for viral replication. J Virol. 66 9 5682 4
Chang C et al 1987 Expression of the precore region of an avian hepatitis B virus is not required for viral replication.J Virol 61 10 3322 5
and Milich D Liang T. J 2003 Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection.Hepatology. 38 5 1075 86
Milich D. R et al 1990Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A. 87 17 6599 603
Terazawa S et al 1991 Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen.Pediatr Res. 29 1 5 9
and Magnius L. O Espmark J. A 1972 New specificities in Australia antigen positive sera distinct from Le Bouvier determinants. J Immunol. 109 5 1017 21
and Petit M. A Pillot J 1985 HBc and HBe antigenicity and DNA binding activity of major core protein 22in hepatitis B virus core particles isolated from human liver cells. J Virol. 53(2):5
Nassal M 1992 The arginine rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly.J Virol. 66 7 4107 16
Hatton T et al 1992RNA and DNA binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J Virol. 66 9 5232 41
Milich D. R 1999Do T cells "see" the hepatitis B core and e antigens differently? Gastroenterology. 116 3 765 8
Milich D. R et al 1998The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid:a mechanism for persistence. J Immunol. 160 4 2013 21
Milich D. R et al 1993Role of T-cell tolerance in the persistence of hepatitis B virus infection. J Immunol Emphasis Tumor Immunol. 14 3 226 33
Zoulim F et al 1994Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol. 68 3 2026 30
Keasler W et al 2007Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J Virol. 81 6 2656 62
Tang H et al 2006Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci. 97 10 977 83
Muroyama R et al 2006Nucletoide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol. 45 6 805 12
Benhenda S et al 2009Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv Cancer Res. 103 75 109
Murakami S 2001Hepatitis B virus x protein: a multifunctional viral regulator. J Gastroenterol. 36 10 651 60
Dane D. S et al 1970Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1 7649 695 8
Kidd- Ljunggren K et al 2006High levels of hepatitis B virus DNA in body fluids from chronic carriers. J Hosp Infect. 64 4 352 7
Qian W. P et al 2005Rapid quantification of semen hepatitis B virus DNA by realtime polymerase chain reaction. World J Gastroenterol. 11 34 5358 9
and Kay A Zoulim F 2007Hepatitis B virus genetic variability and evolution. Virus Res. 127 2 164 76
Araujo N. M et al 2011Hepatitis B virus infection from an evolutionary point of view: How viral, host, and environmental factors shape genotypes and subgenotypes. Infect Genet Evol. 11 6 1199 207
and Lok ASF ( Chu C. J 2002Clinical significance of hepatitis B virus genotypes. Hepatology. 35 5 1274 6
Le Bouvier et al 1972Subtypes of Australia antigen and hepatitis-B virus. JAMA. 222 8 928 30
Galibert et al 1979Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature. 281 5733 646 50
Okamato et al 1988Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 69 2575 83
Kramvis et al 2008Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J Med Virol. 80 1 27 46
Vivekanandan et al 2004Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in Southern India. Clin Infect Dis. 38 9 81 6
Gandhe et al 2003Hepatitis B virus genotypes and serotypes in Western India: lack of clinical significance. J Med Virol. 69 3 324 30
Thakur V et al 2002Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol. 17 2 165 70
Tran et al 2008New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol. 82 11 5657 63
Olinger C et al 2008Possible new hepatitis B virus genotype, Southeast Asia. Emerg Infect Dis. 14 11 1777 80
Tatematsu et al 2009A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol. 83 20 10538 47
Mizokami M et al 1999Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett. 450(1-2):66-71.
Farazmandfar T et al 2012A rapid and reliable genotyping method for hepatitis B virus genotypes (A-H) using type-specific primers. J Virol Methods. 181 1 114 6
Liu et al 2008Genotyping of hepatitis B virus genotypes A to G by multiplex polymerase chain reaction. Intervirology. 51 4 247 52
Chen J et al 2007Improved multiplex-PCR to identify hepatitis B virus genotypes A-F and subgenotypes B1, B2, C1 and C2. J Clin Virol. 38 3 238 43
Teles S. A et al 1999Hepatitis B Virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs. 23 12 1074 8
Welzel T. M et al 2006Real-time PCR assay for detection and quantification of hepatitis B virus genotypes A to G. J Clin Microbiol. 44 9 3325 33
Ganova-raeva L et al 2010Robust hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol. 48 11 4161 8
Guirgis B. S et al 2010Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis. 14 11 941 53
and Bartholomeusz A Schaefer S 2004Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol. 14 1 3 16
and Echevarria J. M Avellon A 2006Hepatitis B Virus genetic diversity. J Med Virol. 78 1 36 42
Schaefer S 2005Hepatitis B virus: significance of genotypes. J Viral Hepat. 12 2 111 24
Janssen H. L et al 2005Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet. 65 9454 123 9
Kao J. H et al 2002Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol. 40 4 1207 9
Livingston S. E et al 2007Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 133 5 1452 7
Whalley S. A et al 2001Kinetics of acute hepatitis B virus infection in humans. J Exp Med. 193 7 847 54
and Girones R Miller R. H 1989Mutation rate of the hepadnavirus genome. Virology. 170 2 595 7
Nowak M. A et al 1996Viral dynamics in hepatitis B virus infections. Proc Natl Acad Sci U S A. 93 9 4398 402
Park S. G et al 2003Fidelity of hepatitis B virus polymerase. Eur J Biochem. 270 14 2929 36
Locarnini S et al 2003The hepatitis B virus and common mutants. Semin Liver Dis. 23 1 5 20
Mizpkami M et al 1997Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol. 44 (1):S 83 90
Mcmahon B. J 2010Natural history of chronic hepatitis B. Clin Liver Dis 14 3 381 96
Wieland S. F et al 2005Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA. 102 28 9913 17
Perrillo R. P 2005Current treatment of chronic hepatitis B: benefits and limitations. Semin. Liver Dis. 25 1 20 28
Zoulim F 2004Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother. 15 6 299 305
Sung J. J et al 2005Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 128 7 1890 97